利奈唑胺对临床分离阳性球菌的体外敏感性分析

目的:对比利奈唑胺与万古霉素及其他几种常用抗菌药物对临床分离阳性球菌的体外抗菌活性。方法:按照NCCLS(CLSI) 2007 纸片扩散法操作标准测定利奈唑胺与其他几种常用抗菌药物的体外抗菌活性。结果:本院分离的耐甲氧西林金黄色葡萄球菌(MRSA) 比例较高(79.1%), 利奈唑胺、万古霉素、替考拉宁的敏感率均达到100% 。耐甲氧西林凝固酶阴性葡萄球菌(MRCNS)的比例较MRSA 高(88.9%), 利奈唑胺与万古霉素、替考拉宁活性相当, 敏感率均为100% 。利奈唑胺对粪肠球菌的活性与万古霉素、替考拉宁相当, 对屎肠球菌的活性优于万古霉素和替考拉宁(100%, 80.4%, 78.1%), 对青霉素耐药的肺炎链球菌(PRSP) 也表现了优越的抗菌活性。结论:对于MRSA、MRCNS、PRSP、粪肠球菌, 利奈唑胺与万古霉素、替考拉宁的活性相当, 均为100% 的敏感率;对屎肠球菌的抗菌活性优于万古霉素和替考拉宁, 是治疗多药耐药阳性球菌感染的新型药物。

Sensitivity analyses of linezolid against clinical gram-positive cocci isolates in vitro

AIM: To compare the antibacterial activity of linezolid with vancomycin and other antibacterials against clinical gram-positive cocci isolates in vitro.METHODS: The antibacterial activity of linezolid and other antibacterials were determined according to the disk diffusion guidelines of NCCLS (CLSI) 2007 in vitro.RESULTS: The incidence of methicillin^- resistant Staphylococcus aureus (MRSA) isolated in our hospital was 79.1%, linezolid showed great susceptibility as well as vancomycin and teicoplanin.The incidence of methicillin-resistant coagulase negative Staphylococcus (MRCNS, 88.9%) was higher than that of MRSA, the antibacterial activity of linezolid was comparable with that of vancomycin and teicoplanin, and the sensitivity was 100%.The activity of linezolid against enterococcus faecalis is similar to that of vancomycin and teicoplanin, the activity of linezolid against enterococcus faecium is prior to that of vancomycin and teicoplanin (100%, 80.4%, 78.1%).Linezolid also showed great activity against penicillin resistant streptococcus pneumonia (PRSP).CONCLUSION: The antibacterial activity of linezolid was comparable with that of vancomycin and teicoplanin against MRSA, MRCNS, PRSP and enterococcus faecalis, and the sensitivity were all 100%.The antibacterial activity was better than those of the two drugs against enterococcus faecium in vitro.Linezolid could be a promising therapeutic option to treat infections caused by multi-resistant gram-positive cocci.